Gentec
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Gentec - overview
Established
1985
Location
Barcelona, -, Spain
Primary Industry
Pharmaceuticals
About
Gentec is a pharmaceutical company focused on manufacturing and distributing over 200 active ingredients, serving pharmaceutical and food sectors with high-quality solutions. Founded in 1985 in Barcelona, Spain, Gentec is engaged in the production and distribution of pharmaceutical active ingredients. The company operates independently without known subsidiaries or parent companies. Jaime Baños serves as the current CEO.
Gentec specializes in the manufacture and distribution of over 200 pharmaceutical active ingredients, including several first-generation compounds. The company's core product offerings include APIs (Active Pharmaceutical Ingredients) for the pharmaceutical industry and raw materials for the food, dietary, and nutritional sectors. Gentec serves a wide client base, including B2B customers like pharmaceutical manufacturers and food producers, and operates across various regions, including Europe, North America, and parts of Latin America. Additionally, Gentec offers services to facilitate legal compliance, market consultancy, and licensing support for product development.
In 2023, Gentec reported a revenue of USD 23. 12 mn and an EBITDA of USD 2. 86 mn. The company's revenue model is based on direct B2B sales of pharmaceutical active ingredients and raw materials, primarily through negotiated contractual agreements with clients, allowing for long-term partnerships in the industry.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.gentec.es
Total Amount Raised
Subscriber access only
Gentec - timeline of key events
Gentec - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 25,180,712.6 | 19,466,827.7 | 14,314,831.4 | 10,373,082.5 | 11,216,988 | 21,092,613 | - | - | - |
| % Revenue Growth (YoY) | - | (22.7%) | (26.5%) | (27.5%) | 8.1% | 88.0% | - | - | - |
| EBITDA (USD) | 199,607.4 | 473,458 | 768,862.1 | 471,678.4 | 556,724.7 | 1,571,847.7 | - | - | - |
| Operating Income (USD) | 136,319.2 | 263,458 | 551,186.6 | 190,749.4 | 251,916.8 | 138,155.9 | - | - | - |
| Operating Margin | 0.5% | 1.4% | 3.9% | 1.8% | 2.2% | 0.7% | - | - | - |
| % EBITDA Margin | 0.8% | 2.4% | 5.4% | 4.5% | 5.0% | 7.5% | - | - | - |
| NET Income (USD) | 14,226,623 | 144,824.9 | 62,092.1 | 63,766.1 | 61,178.7 | 631,611.8 | - | - | - |
| % Net Margin | 56.5% | 0.7% | 0.4% | 0.6% | 0.5% | 3.0% | - | - | - |
Gentec - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.